EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Clinical and microbiologic features of Achromobacter species: a 10-year, multicenter experience

David R Bayless iD, Mitchell G Dumais iD, Jack W McHugh iD, Nischal Ranganath iD, Madiha Fida, Supavit Chesdachai iD, Omar M Abu Saleh

Journal of Clinical Microbiology · 08.10.2025 · 63 (10)

DOI: 10.1128/jcm.00724-25 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 08.10.2025. Verfasst von David R Bayless und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mayo Clinic College of Medicine & Science, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Achromobacter, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Clinical and Translational Science, Mayo Clinic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Achromobacter species are Gram-negative bacilli that predominantly affect individuals with cystic fibrosis or those with immunocompromising conditions. Clinical and microbiologic data on Achromobacter species are limited due to the rarity of these organisms and challenges with species-level identification. We conducted a 10-year retrospective analysis (1 January 2013 to 14 March 2023) of all bloodstream and non-bloodstream Achromobacter isolates identified at three tertiary-care Mayo Clinic locations (Minnesota, Arizona, and Florida). Additionally, we examined clinical characteristics of adult patients with Achromobacter bloodstream isolates. A total of 1,598 Achromobacter isolates, encompassing 1,545 non-bloodstream isolates and 53 bloodstream isolates, were identified. The most frequently identified species was Achromobacter xylosoxidans , though species-level identification was not possible for many isolates. Among adult patients with Achromobacter bloodstream infection, the mean age was 58.3 years (standard deviation ± 16.7), 73.1% had a central venous catheter, and 59.6% were immunocompromised. All-cause mortality was 10.2% at 30 days and 18.4% at 90 days. Bloodstream isolates exhibited greater than 90% susceptibility to meropenem, piperacillin-tazobactam, and trimethoprim-sulfamethoxazole. The respiratory tract was the most common source of non-bloodstream isolates (57.5%). Non-bloodstream isolates showed high susceptibility to imipenem (94.6%), piperacillin-tazobactam (92.8%), trimethoprim-sulfamethoxazole (92.1%), and meropenem (87.5%) while demonstrating significant resistance to fluoroquinolones and aminoglycosides. Our findings support the use of piperacillin-tazobactam, carbapenems, or trimethoprim-sulfamethoxazole as initial therapy for Achromobacter infections. Further research is needed to better define the clinical and microbiologic characteristics of Achromobacter infections. IMPORTANCE Achromobacter is a rare but important genus of bacteria that tends to cause infection in those with cystic fibrosis, recurrent healthcare exposures, and/or an immunocompromising condition. There is limited data on the clinical profile of Achromobacter infections as well as optimal antibiotic selection for affected patients. We conducted a retrospective study to improve understanding of the microbiologic and clinical characteristics of Achromobacter . Our study consists of a 10-year survey of all Achromobacter isolates processed by three Mayo Clinic tertiary-care centers in Minnesota, Florida, and Arizona from 2013 to 2023. We report multiple findings, including the clinical characteristics of patients with Achromobacter bloodstream infection, the number of different Achromobacter species identified, and the sources of isolates not obtained from blood cultures. We additionally present antimicrobial susceptibility results for Achromobacter isolates. Our study provides guidance to clinicians treating Achromobacter infections and, it is hoped, will facilitate ongoing study of Achromobacter .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AchromobacterGram-Negative Bacterial InfectionsHumansRetrospective StudiesFemaleMiddle AgedMaleAnti-Bacterial AgentsAdultAgedMicrobial Sensitivity TestsBacteremiaArizona

Stichwörter der Autor:innen

AchromobacterAchromobacter bloodstream infectionAchromobacter xylosoxidansmulticenter studynon-bloodstream Achromobacter isolates

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Mayo Clinic College of Medicine & Science, Rochester, Minnesota, USA.
  • Department of Medicine, Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic College of Medicine & Science, Rochester, Minnesota, USA.

ORCID-Profile: David R Bayless, Mitchell G Dumais, Jack W McHugh, Nischal Ranganath, Supavit Chesdachai

Förderung

  • Center for Clinical and Translational Science, Mayo Clinic

Zitieren

APA

Bayless, D. R., Dumais, M. G., McHugh, J. W., Ranganath, N., Fida, M., Chesdachai, S., & Abu Saleh, O. M. (2025). Clinical and microbiologic features of Achromobacter species: a 10-year, multicenter experience. Journal of Clinical Microbiology, 63(10). https://doi.org/10.1128/jcm.00724-25

Vancouver

Bayless DR, Dumais MG, McHugh JW, Ranganath N, Fida M, Chesdachai S, et al. Clinical and microbiologic features of Achromobacter species: a 10-year, multicenter experience. Journal of Clinical Microbiology. 2025;63(10). doi:10.1128/jcm.00724-25

BibTeX
@article{Bayless2025,
  author = {Bayless, David R and Dumais, Mitchell G and McHugh, Jack W and Ranganath, Nischal and Fida, Madiha and Chesdachai, Supavit and Abu Saleh, Omar M},
  title = {Clinical and microbiologic features of Achromobacter species: a 10-year, multicenter experience},
  journal = {Journal of Clinical Microbiology},
  year = {2025},
  volume = {63},
  number = {10},
  doi = {10.1128/jcm.00724-25}
}
Kostenlos starten →